ATS 2019 Virtual Final Program

10:50 Where Do We Go From Here? Health Policy and the Advancement of Real World Data R. Califf, MD, Durham, NC 11:10 Questions CLINICAL • TRANSLATIONAL CLINICAL TOPICS IN PULMONARY MEDICINE CME Credits Available: 2 C3 EVIDENCE IN ASTHMA COPD OVERLAP: CLINICAL AND MOLECULAR STUDIES TO ADVANCE TREATMENT Assemblies on Clinical Problems; Allergy, Immunology and Inflammation 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom C Three-Four (Level 2) Target Audience Individuals involved in care of patients with COPD and basic, clinical, and translational researchers focused on COPD Objectives At the conclusion of this session, the participant will be able to: • gain new findings about eosinophilic COPD and evidence for differential treatment responses in this subtype; • learn new findings about the allergic subtype of COPD and evidence for the importance of environmental triggers in this population; • understand and learn new findings about the role of Th2 inflammation in COPD and implications for treatment strategies and drug development. Despite studies showing that individuals with asthma COPD overlap (ACO) have higher risks for adverse outcomes compared to those with asthma or COPD alone, the group with ACO has been difficult to characterize, and definitions of ACO have not been validated in any systematic manner. Regardless, studies have made substantial progress in better characterizing the role of eosinophils, Th2 inflammation and allergic disease in individuals with COPD, therefore providing potentially important insights into ACO. This session will discuss important new clinical, genetic, and translational studies relevant to asthma and COPD with the ultimate goal of advancing strategies to treat this high-risk group. Chairing: S. Christenson, MD, MS, San Francisco, CA N. Putcha, MD, Baltimore, MD M. Van Den Berge, PhD, Groningen, Netherlands 9:15 Eosinophilic COPD: Phenotyping and Treatment Regimens C.E. Brightling, BSc(Hons), MBBS, PhD, Leicester, United Kingdom 9:35 Allergic COPD: Don’t Forget the Environment N. Putcha, MD, Baltimore, MD 9:50 Findings from Genetic Studies of Asthma and COPD: Clues for Asthma COPD Overlap? C.P. Hersh, MD, MPH, ATSF, Boston, MA 10:05 The Type 2 Paradigm and Beyond S. Christenson, MD, MS, San Francisco, CA 10:20 The Severe Asthma Molecular Phenotype as a Mimic of COPD S.E. Wenzel, MD, ATSF, Pittsburgh, PA 10:40 The Role of Mucin Gels in Asthma COPD Overlap R.C. Boucher, MD, Chapel Hill, NC 11:00 The Genomics of Inhaled Corticosteroid Response A. Faiz, PhD, Groningen, Netherlands This session and the International Conference are supported by educational grants from Genentech, Inc., Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests. BEHAVIORAL • CLINICAL CRITICAL CARE TRACK CME Credits Available: 2 MOC Points Available: 2 C4 WHEN THE SUN SETS: NIGHTTIME IN THE ICU Assemblies on Critical Care; Behavioral Science and Health Services Research; Nursing 9:15 a.m. - 11:15 a.m. OMNI DALLAS DOWNTOWN Dallas Ballroom D/H (Level 3) Target Audience Critical care clinicians (physicians, nurses, and other interprofessional team members), trainees who work in the ICU, and ICU administrators Objectives At the conclusion of this session, the participant will be able to: • characterize the differences of clinicians, patients, and families in the ICU overnight vs during the daytime; • understand the impact of overnight ICU staffing patterns on the experience of clinicians, patients, and families; • understand pharmacologic and non-pharmacologic strategies which may be effective in improving the experience of patients in the ICU overnight. In this session, we will explore the different world of the ICU at night from multiple stakeholders’ (physicians, nurses, patients, families) perspectives. Our aims are to elucidate unique challenges faced overnight and to explore potential and/or proven interventions (e.g., changing staffing, using technology, altering the ICU environment, considering pharmacologic therapies) to address these issues. Coming out of this session, learners will understand (1) how and why the ICU is different at night compared to during the day and (2) what is known about how best to optimize care delivery “when the sun sets” to provide the highest quality patient care. Chairing: H.B. Gershengorn, MD, ATSF, Miami, FL M. Hua, MD, MSci, New York, NY S.J. Hsieh, MD, MS, New York, NY 9:15 Why Nighttime Isn’t Just Daytime Without the Sun S.J. Hsieh, MD, MS, New York, NY 9:25 Up-Staffing: Intensivists Onsite Overnight M.P. Kerlin, MD, MS, Philadelphia, PA 9:39 Night vs Day: The Nursing Perspective N.S. McAndrew, PhD, RN, ACNS-BC, CCRN, Milwaukee, WI ATS 2019 • Dallas, TX 222 TUESDAY • MAY 21